Yuki Ushimaru
Papers
4
Total Citations
27
H-Index
2
About
Yuki Ushimaru is a rising surgical oncologist whose work is reshaping the treatment landscape for gastric and gastroesophageal junction cancers. His research centers on two pivotal areas: optimizing minimally invasive surgical techniques and pioneering targeted therapies for advanced disease. Ushimaru has made major contributions to the field by demonstrating the real-world safety and efficacy of zolbetuximab—a novel CLDN18.2-targeted antibody—for patients with HER2-negative advanced gastric cancer, as documented in his highly cited 2025 case series (13 citations). He has also advanced surgical practice by comparing robotic and laparoscopic gastrectomy outcomes, showing comparable three-year survival with improved perioperative performance, and by developing the intracorporeal triangular anastomotic technique for robotic distal gastrectomy, which enhances patient safety and procedural simplicity. His work on conversion surgery following zolbetuximab-based chemotherapy offers new hope for patients with initially unresectable disease. With a growing citation impact and a focus on translating cutting-edge therapies into clinical practice, Ushimaru is establishing himself as a key figure in the next generation of gastric cancer research.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4